GlobeNewswire by notified

Covis Completes Acquisition of Global Respiratory Portfolio of Two Medicines from AstraZeneca

Share

Enters into on an Exclusive Promotion and Distribution Agreement with Novartis for Distribution Rights to Seebri® Breezhaler® and Ultibro® Breezhaler® in Canada

ZUG, Switzerland, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Covis Pharma Group (“Covis”), a global specialty pharmaceutical company that markets therapeutic solutions for patients with life-threatening conditions and chronic illnesses, announced today that Covis Pharma GmbH has completed the acquisition of Eklira® (aclidinium bromide), known as Tudorza® in the US and marketed as Bretaris® in some countries, and Duaklir® (aclidinium bromide/formoterol), marketed as Brimica® in some countries, from AstraZeneca (the “Acquisition”). Under the terms of the Acquisition agreement, AstraZeneca received a payment of $270m from Covis. AstraZeneca will also receive payments in respect of certain ongoing development costs related to the medicines.

In addition, Covis is pleased to announce that it has entered into an Exclusive Promotion and Distribution Agreement (the “Novartis Distribution Agreement”) with Novartis Pharmaceuticals Canada Inc. (“Novartis”), whereby Covis has been appointed as Novartis’ exclusive partner to promote and distribute PrSeebri® Breezhaler® and PrUltibro® Breezhaler® in Canada.

Building upon Covis’ previous acquisition of the global rights to respiratory medicines Alvesco®, Omnaris® and Zetonna® from AstraZeneca in 2018, the completion of the Acquisition and the entering into of the Novartis Distribution Agreement, enables the company to continue to meet one of its key strategic initiatives to become a leading respiratory company by creating a platform to offer a continuum of care for respiratory patients.

“The closing of the acquisition and the expansion of our business in Canada with the Novartis partnership enables Covis to offer a full continuum of best-in-class therapies for allergic rhinitis, asthma and COPD and demonstrates our ability to engage with, and be a partner of choice for, leading pharmaceutical companies,” said Covis CEO Michael Porter. “As previously announced, as a result of the acquisition and this partnership with Novartis, Covis is firmly placed as one of the top 10 respiratory companies in the world. We are excited about our growth in this therapeutic area, and maintaining access to these important therapies for patients and physicians.”

In connection with the Acquisition, Barclays acted as financial advisor to Covis and Paul, Weiss, Rifkind, Wharton & Garrison LLP acted as legal advisor to Covis. Buchanan Ingersoll & Rooney PC, Sidley Austin LLP and Fasken Martineau LLP provided regulatory and intellectual property law advice to Covis.

Aboutthe Medicines

Eklira (aclidinium bromide) and Duaklir (aclidinium bromide/formoterol) are inhaled respiratory medicines used for the maintenance treatment of COPD. Eklira is a long-acting muscarinic antagonist (LAMA), which is marketed in the US as Tudorza and in some countries as Bretaris®. Duaklir is a combination therapy that contains both a LAMA and a long-acting beta2-agonist (LABA). It is marketed in some countries as Brimica®. Both medicines are presented as a dry powder for inhalation and are delivered via a breath-actuated multi-dose dry powder inhaler, Genuair® (Pressair® in the US).

Seebri (glycopyrronium bromide) is a long-acting muscarinic antagonist (LAMA), indicated as a long-term once-daily maintenance bronchodilator treatment in patients with COPD including chronic bronchitis and emphysema. Ultibro (indacaterol maleate/glycopyrronium bromide) is a combination therapy that contains both a LAMA and a long-acting beta2-agonist (LABA). It is indicated for the long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with COPD), including chronic bronchitis and emphysema, and for the reduction of exacerbations of COPD in patients with a history of exacerbations. Both medicines are a dry powder for inhalation via the Breezhaler, a breath-actuated dry powder inhaler.

About Covis
Covis, headquarter in Luxembourg, is a global specialty pharmaceutical company that markets therapeutic solutions for patients with life-threatening conditions and chronic illnesses. Additional information is available at www.covispharma.com.

Trademarks are the property of their respective owners.

Media Contact
info@covispharma.com

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

DNO Receives 10 Awards in Norway's APA Licensing Round18.1.2022 15:54:11 CET | Press release

Oslo, 18 January 2022 – DNO ASA, the Norwegian oil and gas operator, today announced that its wholly-owned subsidiary DNO Norge AS has been awarded participation in 10 exploration licenses, of which three are operatorships, under Norway's Awards in Predefined Areas (APA) 2021 licensing round. Of the 10 new licenses, six are in the North Sea and four in the Norwegian Sea. At yearend 2021, DNO held interests in 73 licenses offshore Norway, of which 17 were operated by the Company. The new awards under the APA 2021 licensing round include: PL 586 B: Neptune Energy Norge AS (operator), Suncor Energy Norge AS, Vår Energi AS, DNO Norge AS (7.5%) PL 923 B: Equinor Energy AS (operator), Petoro AS, Wellesley Petroleum AS, DNO Norge AS (20%) PL 969 B: A/S Norske Shell (operator), Spirit Energy Norway, DNO Norge AS (45%) PL 1007 B: DNO Norge AS (operator, 40%), OMV (Norge) AS, Equinor Energy AS, Spirit Energy Norway AS PL 1145: DNO Norge AS (operator, 60%), Aker BP ASA PL 1146: ConocoPhillips Ska

AGC Biologics Names Regina Choi-Rivera New General Manager of Boulder, Colorado Mammalian Production Facility18.1.2022 15:05:00 CET | Press release

Boulder, Colo., Jan. 18, 2022 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced Regina Choi-Rivera as the new General Manager of the company’s large-scale biopharmaceutical mammalian production facility in Boulder. In this role, she assumes executive oversight and leadership and will manage strategic development and facility operations. “We’re incredibly excited that Ms. Choi-Rivera is joining AGC Biologics as the General Manager at our Boulder facility. She brings tremendous experience in both GMP manufacturing and project management,” said AGC Biologics Executive Vice President of U.S. Operations, J.D. Mowery. “Her breadth of knowledge and proven leadership give me great confidence that she is the right leader for our team, as well as our customers.” Ms. Choi-Rivera brings more than 25 years of experience in the biotech industry to this role and joins AGC Biologics after working for Samsun

Solidium’s CEO to change18.1.2022 14:01:05 CET | Press release

Solidium’s CEO, Antti Mäkinen, will leave his position as the CEO of Solidium on 31st May 2022. Mäkinen, 60, has acted as CEO of the company since year 2017. “The past five years have been rewarding and I have had the opportunity to work with an excellent team and great portfolio companies. Solidium has an established position and a strong track in growing shareholder value”, says Mäkinen. Antti Mäkinen has acted as a Board Member and Chairman of the Shareholders’ Nomination Committee in many of Solidium’s portfolio companies. He is still nominated this Spring in the Annual General Meetings i.a. as the Chairman of the Board in Stora Enso and a Member of the Board in Metso Outotec. The Chairman of the Board of Solidium, Harri Sailas, would like to thank Mäkinen for his work both in charge of Solidium and as Solidium’s representative in the portfolio companies. “In Antti Mäkinen’s steering, Solidiums position has stabilized and the company has been more active both as an owner and in mak

Solidiums verkställande direktör avgår18.1.2022 14:01:05 CET | Pressemelding

Solidiums verkställande direktör Antti Mäkinen lämnar sin post som VD den 31 maj 2022. Mäkinen, 60, har verkat i företagets ledning från och med år 2017. ”De senaste fem åren har varit givande och jag har fått arbeta med ett utmärkt team och fina portföljbolag. Solidium har en stabil position och bevisad förmåga att öka innehavens ägarvärde”, säger Mäkinen. Antti Mäkinen har verkat i flera av Solidiums portföljbolag som styrelsemedlem och som ordförande i aktieägarnas nomineringskommitté. Han är fortfarande nominerad i vårens bolagsstämmor bland annat som styrelseordförande i Stora Enso och styrelsemedlem i Metso Outotec. Solidiums styrelseordförande Harri Sailas tackar Mäkinen för arbetet både inom Solidiums ledning och som representant i Solidiums portföljbolag. ”Under ledning av Antti Mäkinen har Solidiums position etablerat sig och företaget har aktiverat sig både som ägare och vid att göra nya placeringar. Hans agerande har väckt uppskattning i alla företagets intressegrupper”, sä

RESULT OF RIKSBANK REVERSED AUCTIONS SEK MUNICIPAL BONDS18.1.2022 11:30:00 CET | Press release

AuctionAuction resultsAuction date2022-01-18Maturity2024Tendered volume, SEK mln750 +/- 750Offered volume, SEK mln1593Volume bought, SEK mln1500Number of bids19Number of accepted bids19 QuarterQuarter 1Quarter 2Quarter 3Quarter 4Offered volume, SEK mln720205600Volume bought, SEK mln627205600Number of bids4310Number of accepted bids4310Average DM-0.166-0.139-0.129-Lowest accepted DM-0.179-0.160-0.129-Highest DM-0.129-0.139-0.129-Accepted at lowest DM0.814100.00100.00- QuarterQuarter 1Quarter 2Quarter 3Quarter 4Offered volume, SEK mln4081001000Volume bought, SEK mln4081001000Number of bids7310Number of accepted bids7310Average DM-0.133-0.129-0.140-Lowest accepted DM-0.160-0.129-0.140-Highest DM-0.120-0.129-0.140-Accepted at lowest DM100.00100.00100.00-

Aspo subsidiary ESL Shipping continues fleet renewal in accordance with its strategy by selling the barge Espa18.1.2022 11:15:00 CET | Press release

Aspo Plc Press Release January 18, 2022, at 12.15 p.m. Aspo subsidiary ESL Shipping continues fleetrenewal in accordance with its strategy by selling the barge Espa Aspo’s ESL Shipping continues fleet renewal by selling its smallest, 9000 dwt towable barge Espa to Raduga Shipping and Trading OÜ. The transaction was concluded and Espa subsequently delivered to her new owner today 18th of January. A sales gain of approximately 1.4 million euros will be recorded in the profit of ESL Shipping’s first quarter. Espa was built in 1987 as the last vessel of the Vuosaari shipyard in Helsinki. She was designed and equipped for efficient transportation and lightering of energy coal cargoes to powerplants in Helsinki. In recent years she was mainly used for cement industry transport demand. She also spent one summer as a floating beach volley field in Helsinki. Peculiarities in Finnish shipping policy led to increasing cost of barge towing tugboats, as tugboat crew could not receive state support